Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival
Author:
Affiliation:
1. Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
2. Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.00225
Reference23 articles.
1. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint
2. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
3. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
4. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?;Journal of Medicinal Chemistry;2024-09-10
2. Monitoring Overall Survival in Pivotal Trials in Indolent Cancers;Statistics in Biopharmaceutical Research;2024-09-03
3. The AST/ALT ratio predicts survival and improves oncological therapy decisions in patients with non-small cell lung cancer receiving immunotherapy with or without radiotherapy;Frontiers in Oncology;2024-08-26
4. US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma;Journal of Clinical Oncology;2024-07-25
5. Improving Collection and Analysis of Overall Survival Data;Clinical Cancer Research;2024-07-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3